GlassScriptPhysician profile
Amanda Danielle Spinuzzi
NPI 1851063481
$830.46
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.80 · 2022: $402 · 2023: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.96 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $62.09 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.66 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $49.36 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $49.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $47.57 | 2022-2023 | Breztri |
| Lilly USA, LLC | $44.12 | 2022-2023 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.65 | 2022-2023 | Caplyta |
| Novo Nordisk INC | $30.05 | 2022-2023 | |
| Uswm, LLC | $29.68 | 2021-2022 | |
| Insulet Corporation | $23.24 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.83 | 2021 | |
| Pfizer INC. | $16.31 | 2022 | |
| Amgen INC. | $15.17 | 2023 | Evenity, Prolia |
| Collegium Pharmaceutical, INC. | $14.46 | 2023 | Xtampza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Spinuzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.